Subscribe to Newsletter

Business & Regulation


Business & Regulation Trends & Forecasts

Quality Over Quantity: EMA's New Approach to Biosimilars

| Rob Coker | 2 min read

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.

Business & Regulation Standards & Regulation

Trump's New Push on Drug Pricing

| Rob Coker | 2 min read

Trump signs executive order on lowering drug prices and amends Medicare price negotiation for small molecule drugs.

Business & Regulation Profession

From Benchtop Chemist to CEO

| Stephanie Vine | 5 min read

Simon Tasker joined Colorcon as a bench chemist – and never left. Today, he’s the company’s CEO. Here’s how his career unfolded.

Business & Regulation Standards & Regulation

Disrupted Development

| Rob Coker | 3 min read

The political situation in the US and its impact on science and medicine is changing rapidly. Here’s a quick look at the latest developments.

Business & Regulation Profession

The Blood Cancer Success Story: Part 2

| Stephanie Vine | 6 min read

Lore Gruenbaum discusses The Leukemia & Lymphoma Society, advances in blood cancers, and the role of nonprofits.

Business & Regulation Bioprocessing - Upstream & Downstream

ADC Innovation: The Road Ahead

| Rob Coker | 5 min read

ADCs have shown their promise, but the next step is realizing their potential.

Business & Regulation Standards & Regulation

FDA to Phase Out Animal Testing

| Rob Coker | 2 min read

FDA to phase out mandatory animal testing with human-relevant methods for drug development

Business & Regulation Standards & Regulation

Trump Speech Suggests Pharma Tariffs Incoming

| Stephanie Vine | 2 min read

Donald Trump threatens “major tariff” on pharmaceuticals.

Business & Regulation Standards & Regulation

Sitting Down With… The Past: Kowid Ho

| 3 min read

We dive into the archive of 2022 for insight and inspiration – this time with Kowid Ho

Business & Regulation Profession

The Blood Cancer Success Story: Part 1

| Stephanie Vine | 7 min read

Lore Gruenbaum tells us about her career spanning big pharma, biotech and now The Leukemia & Lymphoma Society.


Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register